A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs TAK 831 (Primary)
  • Indications Ataxia; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 25 Jul 2017 New trial record
    • 21 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top